Cannabis sativa is the most well-known plant containing phytocannabinoids. The two most intensely studied phytocannabinoids from this plant are delta-9-tetrahydrocannabidiol (THC) and cannabidiol (CBD). CBD lacks the psychotropic effects of THC and has been a prominent subject of research for medical uses (Brenneisen, 2007). Hemp products (cannabis plant certified to contain less than 0.3% THC by dry weight) have exploded in popularity in recent years largely due to the 2018 Farm Bill (Congress. gov, 2017-2018) which descheduled hemp and hemp seeds and declared hemp an eligible crop under the federal crop insurance program.Cannabidiol has demonstrated interaction with a wide range of receptors in humans and pre-clinical models, including CB1, CB2, GPR3, GPR6, GPR 12, GPR55, TRPV1, 5HT1, PPARγ, D2 high, mu, and delta (Peres et al., 2018). There is also evidence that CBD inhibits certain subunits of the cytochrome P450 system (CYP450) of the liver (Yamaori et al., 2011) and may interact with the orexin/hypocretin system (Murillo-Rodríguez et al., 2019). Given its purported widespread biological activity, CBD has received attention as a potential therapeutic for numerous disease processes.